Cannabis
Cannabis compounds CBD and THC show targeted effects against ovarian cancer cells in lab study
Reported by AI Image generated by AI Fact checked
Laboratory research led by scientists at Khon Kaen University indicates that cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC), two key cannabis compounds, can slow the growth and spread of ovarian cancer cells in vitro, particularly when used together in a 1:1 ratio, while causing relatively limited damage to healthy cells. The early-stage findings, reported in Frontiers in Pharmacology, suggest a potential avenue for future ovarian cancer treatments but are far from clinical use.
A major review published in The Lancet Psychiatry concludes that medicinal cannabis does not effectively treat anxiety, depression or post-traumatic stress disorder. The analysis of 54 randomized controlled trials over 45 years found limited evidence for other conditions like insomnia and autism. Researchers warn of potential harms including psychosis risk and delayed effective treatments.
Reported by AI
A revised ordinance will ban consumer products containing cannabis-derived CBN starting in June. Only patients with specific conditions, such as intractable diseases without alternative treatments, will be allowed to use them.
Emergency departments have reported a steady increase in patients with severe vomiting linked to chronic cannabis use over the past decade. On October 1, the World Health Organization added a specific diagnostic code for cannabis hyperemesis syndrome to its ICD-10 manual, aiding clinicians in identification and tracking. This update highlights a condition that puzzles patients and doctors alike, with relief often found in unexpected remedies.
Reported by AI
Researchers at McGill University have discovered that combining cannabis and tobacco use alters brain chemistry, potentially increasing anxiety and complicating quitting efforts. PET scans of young adults showed elevated levels of an enzyme that breaks down the mood-regulating 'bliss molecule' anandamide in co-users. The findings highlight a molecular mechanism behind worse outcomes for those using both substances.